Application of clotrimazole via a novel controlled release device provides potent retinal protection

详细信息    查看全文

• 作者：Zhaleh Kashkouli Nezhad ; Nobuhiro Nagai…
• 刊名：Journal of Materials Science Materials in Medicine
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：26
• 期：9
• 全文大小：1,033 KB
• 参考文献：1.Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20(6):705-2.CrossRef
  2.Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-3.CrossRef
  3.Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-0.CrossRef
  4.Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-2.CrossRef
  5.Roth F, Bindewald A, Holz FG. Keypathophysiologic pathways in age-related macular disease. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):710-.CrossRef
  6.Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32.
  7.Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115-4.CrossRef
  8.Sur A, Kesaraju S, Prentice H, Ayyanathan K, Baronas-Lowell D, Zhu D, Hinton DR, Blanks J, Weissbach H. Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-alpha. Proc Natl Acad Sci USA. 2014;111(47):16754-.CrossRef
  9.Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008;13(3-):135-3.
  10.Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57(14):2010-2.CrossRef
  11.Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479-8.CrossRef
  12.Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36(9):1893-03.
  13.Nagai N, Kaji H, Onami H, Ishikawa Y, Nishizawa M, Osumi N, Nakazawa T, Abe T. A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye. Acta Biomater. 2014;10(2):680-.CrossRef
  14.Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52(1):37-8.CrossRef
  15.Wang ZY, Zhang HY. Rational drug repositioning by medical genetics. Nat Biotechnol. 2013;31(12):1080-.CrossRef
  16.Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, Amarnath S, Fowler DH, Radwan M, Young MT, Pittman K, Kubes P, Agarwal HK, Parang K, Hinton DR, Bastos-Carvalho A, Li S, Yasuma T, Mizutani T, Yasuma R, Wright C, Ambati J. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. 2014;346(6212):1000-.CrossRef
  17.Yoshida Y, Aoyama Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol. 1987;36(2):229-5.CrossRef
  18.Vanden Bossche H, Marichal P, Gorrens J, Coene MC, Willemsens G, Bellens D, Roels I, Moereels H, Janssen PA. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses. 1989;32(Suppl 1):35-2.CrossRef
  19.Tiffert T, Ginsburg H, Krugliak M, Elford BC, Lew VL. Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. Proc Natl Acad Sci USA. 2000;97(1):331-.CrossRef
  20.McLean KJ, Marshall KR, Richmond A, Hunter IS, Fowler K, Kieser T, Gurcha SS, Besra GS, Munro AW. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology. 2002;148(Pt 10):2937-9.CrossRef
  21.Isaev NK, Stelmashook EV, Dirnagl U, Andreeva NA, Manuhova L, Vorobjev VS, Sharonova IN, Skrebitsky VG, Victorov IV, Katchanov J, Weih M, Zorov DB. Neuroprotective effects of the antifungal drug clotrimazole. Neuroscience. 2002;113(1):47-3.CrossRef
  22.Iannelli A, de Sousa G, Zucchini N, Peyre L, Gugenheim J, Rahmani R. Clotrimazole protects the liver against normothermic ischemia-reperfusion injury in rats. Transplant Proc. 2009;41(10):4099-04.CrossRef
  23.Osmanagaoglu MA, Kesim M, Yulug E, Mentese A, Karahan SC. Ovarian-protective effects of clotrimazole on ovarian ischemia/reperfusion injury in a rat ovarian-torsion model. Gynecol Obstet Invest. 2012;74(2):125-0.CrossRef
  24.Hayami K, Unoki K. Photoreceptor protection against constant light-induced damage by isopropyl unoprostone, a prostaglandin F(2alpha) metabolite-related compound. Ophthalmic Res. 2001;33(4):203-.CrossRef
  25.Imai S
• 作者单位：Zhaleh Kashkouli Nezhad (1)
  Nobuhiro Nagai (1)
  Kotaro Yamamoto (2)
  Hirokazu Kaji (3)
  Matsuhiko Nishizawa (3)
  Hideyuki Saya (4)
  Toru Nakazawa (2)
  Toshiaki Abe (1)
  
  1. Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan
  2. Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
  3. Department of Bioengineering and Robotics, Graduate School of Engineering, Tohoku University, 6-6-01 Aramaki, Aoba-ku, Sendai, 980-8579, Japan
  4. Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
  
• 刊物类别：Chemistry and Materials Science
• 刊物主题：Chemistry
  Biomaterials
  Characterization and Evaluation Materials
  Polymer Sciences
  Metallic Materials
  Ceramics,Glass,Composites,Natural Materials
  Surfaces and Interfaces and Thin Films
  
• 出版者：Springer Netherlands
• ISSN：1573-4838

文摘

Age-related macular degeneration is the leading cause of legal blindness among older individuals. Therefore, the development of new therapeutic agents and optimum drug delivery systems for its treatment are crucial. In this study, we investigate whether clotrimazole (CLT) is capable of protecting retinal cells against oxidative-induced injury and the possible inhibitory effect of a sustained CLT-release device against light-induced retinal damage in rats. In vitro results indicated pretreatment of immortalized retinal pigment epithelium cells (RPE-J cells) with 10-0 μM CLT before exposure to oxygen/glucose deprivation conditions for 48 h decreased the extent of cell death, attenuated the percentage of reactive oxygen species-positive cells, and decreased the levels of cleaved caspase-3. The device consists of a separately fabricated reservoir, a CLT formulation, and a controlled release cover, which are made of poly(ethyleneglycol) dimethacrylate (PEGDM) and tri(ethyleneglycol) dimethacrylate (TEGDM). The release rate of CLT was successfully tuned by changing the ratio of PEGDM/TEGDM in the cover. In vivo results showed that use of a CLT-loaded device lessened the reduction of electroretinographic amplitudes after light exposure. These findings indicate that the application of a polymeric CLT-loaded device may be a promising method for the treatment of some retinal disorders. Zhaleh Kashkouli Nezhad and Nobuhiro Nagai have contributed equally to this work.